» Articles » PMID: 9234523

Mucosal Immunization with DNA-liposome Complexes

Overview
Journal Vaccine
Date 1997 Jun 1
PMID 9234523
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The mucosal surfaces represent the primary site for transmission of several viruses including HIV. To prevent mucosal transmission and dissemination to the regional lymph nodes, an effective HIV vaccine may need to stimulate immune responses at the genital and rectal mucosa. Optimal induction of mucosal immunity in general requires targeting antigens to the specialized antigen presenting cells of mucosal associated lymphoid tissues. The nasal mucosa may provide a simple, non-invasive route to deliver DNA encoding the introduced gene to stimulate mucosal immunity. As a first step to evaluate the feasibility of this approach, we have investigated as a model system, systemic and mucosal immune responses elicited to firefly luciferase generated by DNA immunization. Incorporating DNA into liposomes with cationic lipids enhanced luciferase expression in nasal tissue, and was associated with induction of a humoral response in serum and vaginal fluids and also a proliferative and cytotoxic T lymphocyte response in the spleen and iliac lymph nodes draining the genital and rectal mucosa.

Citing Articles

An Update on the HIV DNA Vaccine Strategy.

Hokello J, Sharma A, Tyagi M Vaccines (Basel). 2021; 9(6).

PMID: 34198789 PMC: 8226902. DOI: 10.3390/vaccines9060605.


Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes.

Mann J, McKay P, Fiserova A, Klein K, Cope A, Rogers P J Virol. 2014; 88(12):6959-69.

PMID: 24719412 PMC: 4054344. DOI: 10.1128/JVI.00183-14.


Mucosal application of gp140 encoding DNA polyplexes to different tissues results in altered immunological outcomes in mice.

Mann J, McKay P, Arokiasamy S, Patel R, Tregoning J, Shattock R PLoS One. 2013; 8(6):e67412.

PMID: 23826293 PMC: 3691144. DOI: 10.1371/journal.pone.0067412.


Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection.

Mann J, McKay P, Arokiasamy S, Patel R, Klein K, Shattock R J Control Release. 2013; 170(3):452-9.

PMID: 23774102 PMC: 3767111. DOI: 10.1016/j.jconrel.2013.06.004.


Vaccine design for CD8 T lymphocyte responses.

Koup R, Douek D Cold Spring Harb Perspect Med. 2012; 1(1):a007252.

PMID: 22229122 PMC: 3234456. DOI: 10.1101/cshperspect.a007252.